CML PHARMACY PROGRAM

Novartis Pharmaceuticals Australia Pty Limited is pleased to be partnering with PharmaPrograms to provide community pharmacies the opportunity to participate in the CML (Chronic Myeloid Leukemia) Pharmacy Program. This program supports patients diagnosed with Chronic Myeloid Leukemia (CML) by prompting symptom review and earlier intervention, aligned with quality use of medicines principles to optimise treatment outcomes. The CML Pharmacy Program is available to adults diagnosed with CML prescribed a tyrosine kinase inhibitor (TKI).